Active Ingredient(s): Erdafitinib
FDA Approved: * April 12, 2019
Pharm Company: * JANSSEN BIOTECH
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Balversa Overview

Erdafitinib is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) approved for treatment of cancer and marketed under the name Balversa. FGFRs are a subset of tyrosine kinases which are unregulated in some tumors and influence tumor cell differentiation, proliferation, angiogenesis, and cell survival.[1][2] Astex Pharmaceuticals discovered the drug and licensed it to Janssen Pharmaceuticals for further development.[1] Researc...

Read more Balversa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Balversa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 3mg, 4mg, 5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Balversa: (3 results)

Sorted by National Drug Code
  • 59676-030 Balversa 3 mg Oral Tablet, Film Coated by Janssen Products Lp
  • 59676-040 Balversa 4 mg Oral Tablet, Film Coated by Janssen Products Lp
  • 59676-050 Balversa 5 mg Oral Tablet, Film Coated by Janssen Products Lp

Other drugs which contain Erdafitinib or a similar ingredient: (1 result)